Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis

Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis

Identifying the biological change from hormone-naïve prostate cancer to castration-resistant prostate cancer (CRPC) is a major clinical challenge for developing therapeutic agents. Although the pathways that lead to CRPC are not fully completely understood, recent evidence demonstrates that androgen...

Full description

Bibliographic Details
Main Authors:	Ann-Yae Na, Soyoung Choi, Eunju Yang, Kwang-Hyeon Liu, Sunghwan Kim, Hyun Jin Jung, Youngshik Choe, Yun-Sok Ha, Tae Gyun Kwon, Jun Nyung Lee, Sangkyu Lee
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Cancers
Subjects:	prostate cancer androgen deprivation therapy comparative proteomics castration-resistant prostate cancer FOXA1 HMGN
Online Access:	https://www.mdpi.com/2072-6694/13/14/3432

Similar Items

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
by: Shinichi Sakamoto, et al.
Published: (2019-04-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
by: Renée de Leeuw, et al.
Published: (2020-10-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
by: Matteo Capaia, et al.
Published: (2018-06-01)

Diferelin® as an effective chemical castration agent for patients with prostate cancer
by: K. M. Nyushko, et al.
Published: (2021-02-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients
by: Shangqian Wang, et al.
Published: (2020-05-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients
by: Mark A. Underwood, et al.
Published: (2013-08-01)

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy
by: Masaki eShiota, et al.
Published: (2016-01-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer
by: Tingmang Yan, et al.
Published: (2021-04-01)

Response and Resistance in Castration-Resistant Prostate Cancer
Published: (2020)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
by: Osamu Ogawa, et al.
Published: (2013-07-01)

Hexane Insoluble Fraction from Purple Rice Extract Retards Carcinogenesis and Castration-Resistant Cancer Growth of Prostate Through Suppression of Androgen Receptor Mediated Cell Proliferation and Metabolism
by: Ranchana Yeewa, et al.
Published: (2020-02-01)

Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer
by: AD Zarrabi, et al.
Published: (2011-06-01)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
by: Yuki Kita, et al.
Published: (2018-09-01)

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth
by: Luo J, et al.
Published: (2020-09-01)

An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia
by: B. Ya. Alekseev, et al.
Published: (2020-11-01)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
by: Masaki Shiota, et al.
Published: (2018-12-01)

Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
by: Crawford ED, et al.
Published: (2020-07-01)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
by: Marzieh Ehsani, et al.
Published: (2021-03-01)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
by: Kouji Izumi, et al.
Published: (2017-10-01)

Long non-coding RNAs in castration-resistant and neuroendocrine prostate cancer: Potential role and therapeutic impact
by: Kumari S. Prajapati, et al.
Published: (2020-12-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer
by: Diane Ojo, et al.
Published: (2015-11-01)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01)

Metastatic castration-resistant prostate cancer: a current view on drug therapy and alternative tumor cell regulation
by: R. A. Gafanov, et al.
Published: (2018-04-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
by: Namrata Khurana, et al.
Published: (2020-01-01)

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies
by: Spitz A, et al.
Published: (2016-08-01)